December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

31.84 +0.50 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Law Offices of Howard G. Smith Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Law Offices of Frank R. Cruz Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Deadline to Lead in Securities Fraud Lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) is May 5, 2026 - Contact Kaplan Fox
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Soleno Therapeutics (NASDAQ:SLNO) Beats Q4 2025 Estimates Amid Cautious Market Reaction to VYKAT XR Launch ↗
Via Chartmill
News headline image
Deadline to Lead in Securities Fraud Lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) is May 5, 2026 - Contact Kaplan Fox
NEW YORK, NY - March 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SOLENO THERAPEUTICS, INC. (SLNO) INVESTOR ALERT Investors With Large Losses in Soleno Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Kaplan Fox Alerts Investors to a Securities Class Action Against Soleno Therapeutics, Inc. (SLNO) - Deadline is May 5, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Alerts Investors to a Securities Class Action Against Soleno Therapeutics, Inc. (SLNO) - Deadline is May 5, 2026
NEW YORK, NY - March 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SLNO
From DJS Law Group
Via Business Wire
News headline image
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Soleno Therapeutics, Inc. (SLNO) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Kaplan Fox Encourages Investors of Soleno Therapeutics, Inc. (SLNO) to Contact the Firm Before Lead Plaintiff Deadline on May 5, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Encourages Investors of Soleno Therapeutics, Inc. (SLNO) to Contact the Firm Before Lead Plaintiff Deadline on May 5, 2026
NEW YORK, NY - March 9, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Securities Fraud Investigation Into Soleno Therapeutics, Inc. (SLNO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
SLNO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
News headline image
INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit filed by Robbins Geller Rudman & Dowd LLP
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. 
Via Stocktwits
News headline image
Soleno (SLNO) Q4 2025 Earnings Call Transcript ↗
Soleno (SLNO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud Investigation
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.
From Kirby McInerney LLP
Via Business Wire
News headline image
SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.